C
Calidi Biotherapeutics Inc
AMEX:CLDI
Calidi Biotherapeutics Inc
AMEX:CLDI
Price:
0.2164
USD
-8.69%
Market Closed
Market Cap:
$2.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Calidi Biotherapeutics Inc
AMEX:CLDI
|
US |
Balance Sheet
Balance Sheet Decomposition
Calidi Biotherapeutics Inc
Calidi Biotherapeutics Inc
Balance Sheet Decomposition is not available for
Calidi Biotherapeutics Inc
Calidi Biotherapeutics Inc
Balance Sheet
Calidi Biotherapeutics Inc
Calidi Biotherapeutics Inc
Currency: USD
| Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
0
|
1
|
0
|
2
|
10
|
6
|
|
| Cash |
0
|
1
|
0
|
2
|
10
|
6
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
0
|
2
|
1
|
1
|
|
| Total Current Assets |
1
|
3
|
1
|
4
|
10
|
6
|
|
| PP&E Net |
1
|
1
|
1
|
5
|
4
|
2
|
|
| PP&E Gross |
1
|
1
|
1
|
5
|
4
|
2
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
1
|
1
|
2
|
|
| Long-Term Investments |
1
|
0
|
1
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
2
N/A
|
3
+83%
|
3
-23%
|
10
+286%
|
14
+42%
|
9
-38%
|
|
| Liabilities | |||||||
| Accounts Payable |
1
|
1
|
2
|
3
|
2
|
1
|
|
| Accrued Liabilities |
2
|
4
|
5
|
6
|
4
|
3
|
|
| Short-Term Debt |
2
|
4
|
3
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
3
|
1
|
3
|
1
|
3
|
0
|
|
| Other Current Liabilities |
1
|
17
|
30
|
0
|
1
|
0
|
|
| Total Current Liabilities |
9
|
26
|
43
|
10
|
9
|
4
|
|
| Long-Term Debt |
6
|
0
|
0
|
2
|
1
|
1
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
6
|
2
|
0
|
|
| Total Liabilities |
15
N/A
|
26
+70%
|
43
+67%
|
18
-58%
|
13
-31%
|
5
-60%
|
|
| Equity | |||||||
| Common Stock |
9
|
9
|
10
|
0
|
0
|
0
|
|
| Retained Earnings |
34
|
45
|
70
|
100
|
122
|
142
|
|
| Additional Paid In Capital |
12
|
13
|
20
|
91
|
123
|
145
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
13
N/A
|
23
-68%
|
41
-81%
|
8
+80%
|
2
N/A
|
4
+145%
|
|
| Total Liabilities & Equity |
2
N/A
|
3
+83%
|
3
-23%
|
10
+286%
|
14
+42%
|
9
-38%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
2
|
7
|
|
Switch to:
Switch to:
See Also
Discover More
